poisar

Stock

MiNK Therapeutics, Inc. INKT

$11.21+0.00%

Overview

INKT market data

Price History

INKT price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.65
Diluted earnings per share over the trailing twelve months.
Beta
0.52
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$8.48 – $21.50
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $52.5 · P/B 6.29.

Company news

10 captured
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyBenzinga · Jun 2, 2026, 2:15 PM
MiNK Therapeutics shares are trading higher. The company announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 with standard of care vs placebo with SOC in patients with severe acute lung injury and critical illness.Benzinga · May 28, 2026, 3:22 PM
MiNK Therapeutics Announces First Patient Dosed In Randomized Phase 2 Clinical Trial Evaluating Agent-797 With SOC Vs Placebo With SOC In Patients With Severe Acute Lung Injury And Critical IllnessBenzinga · May 28, 2026, 1:10 PM
MiNK Therapeutics Presents New Clinical, Translational Data On Agent-797 Showing Pathogen Suppression, Lung Immune Restoration And Tissue Repair Activation, Supporting Ongoing Phase 2 Trial, At ATS 2026Benzinga · May 20, 2026, 3:15 PM
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price TargetBenzinga · May 18, 2026, 3:15 PM
Transcript: MiNK Therapeutics Q1 2026 Earnings Conference CallBenzinga · May 15, 2026, 1:50 PM
8-K filing — MiNK Therapeutics, Inc. (INKT)SEC EDGAR · May 15, 2026, 12:03 PM
MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) EstimateBenzinga · May 15, 2026, 11:40 AM
MiNK Therapeutics Initiates Randomized Phase 2 Trial For agenT-797 In Severe Acute Lung Injury And Respiratory Distress, With Preliminary Data Expected In H2 Of 2026Benzinga · May 15, 2026, 11:40 AM
Earnings Scheduled For May 15, 2026Benzinga · May 15, 2026, 11:15 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock